EPRX: Once-yearly dosing and strong safety position the therapy for leadership in EoE and beyond
EoE is a rapidly growing market with significant unmet need, and the therapy’s once-yearly, physician-administered dosing offers strong compliance and commercial advantages. Detailed interim phase II-B data in December will address efficacy, durability, and safety, supporting expansion into additio…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.